Webb26 okt. 2024 · Chair: Sharon Benzeno, Adaptive Biotechnologies Biomarkers to Guide Immunotherapy Chair: TBD Additional Emerging Therapeutics track themes focus on COVID Therapeutics on Day 1 The COVID Therapeutics Track (Day 1) SARS-CoV-2 vaccines: different vaccine strategies and robustness to viral evolution Webb19 aug. 2014 · Sharon Benzeno Adaptive Biotechnologies Abstract and Figures Part 2 of this two-part article analyses the new data-driven decision-making approaches that are making a difference to life science...
Did you know?
Webb9 mars 2024 · In this new role, Dr. Benzeno will continue to build out the necessary capabilities and partnerships to generate multiple opportunities stemming from … WebbDr. Sharon Benzeno is the Chief Commercial Officer, Immune Medicine and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial-stage biotech company that …
WebbSharon Benzeno, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies. Francesco Berlanda Scorza, Director GVGH, GSK Vaccines for Global Health (GVGH) Valentina Bernasconi, Scientist, CEPI. Jay Berzofsky, Branch Chief, Vaccine Branch, National Cancer Institute - NIH. WebbDr. Sharon Benzeno is the Chief Business Development Officer and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial-stage biotech company that …
Webb12 jan. 2024 · Adaptive Biotechnologies ... Heather M. Callaway, 1 Kathryn M. Hastie, 1 Sharon L. Schendel, 1 Haoyang Li, 1 Xiaoying Yu, 1 Jeremy Shek, 1 Tierra Buck, 1 Sean Hui, 1 Dan Bedinger, 2 Camille Troup, 2 S. Moses Dennison, 3 Kan Li, 3 Michael Alpert, 4 Charles C. Bailey, 4 Sharon Benzeno, 5 Jody L. Bonnevier, 6 Jin-Qiu Chen, 7 Charm Chen ... WebbSharon Benzeno is a Chief Business Development Officer. Dr. Benzeno has 15 years of biopharmaceutical experience in oncology, therapeutics, R&D and M&A. Prior to joining …
WebbADPT - key executives, insider trading, ownership, revenue and average growth rates. Detailed company description & address for Adaptive Biotechnologies Corp..
WebbSharon Benzeno is Chief Commercial Officer-Immune Medicine at Adaptive Biotechnologies Corp. In the past Dr. Benzeno was Senior Scientific Manager at AstraZeneca Plc and Senior Manager at Capgemini... impact now pretoriaWebbDr. Sharon Benzeno is the Chief Commercial Officer, Immune Medicine and leads the Drug Discovery group of Adaptive Biotechnologies, a commercial stage biotech company that … impact number fontWebb12 jan. 2024 · Benzeno S 5, Bonnevier JL 6, Chen JQ 7 ... Adaptive Biotechnologies, 1551 ... , 1 Tierra Buck, 1 Sean Hui, 1 Dan Bedinger, 2 Camille Troup, 2 S. Moses Dennison, 3 Kan Li, 3 Michael D. Alpert, 4 Charles C. Bailey, 4 Sharon Benzeno, 5 Jody L. Bonnevier, 6 Jin-Qiu Chen, 7 Charm Chen, 7 Hyeseon Cho, 8, 9 Peter D. Crompton, 8, 9 Vincent ... impact number of journalsWebbTrack Chair: Sharon Benzeno, Adaptive Biotechnologies PMWC 2024 Luminary Award Ceremony Honoree: Bruce Levine, University of Pennsylvania Advance and Optimize Cell Therapies in Oncology (PANEL) Chair: Sharon Benzeno, Adaptive Biotechnologies - Ira Mellman, Genenetch - Mark Selby, Walking Fish Therapeutics - Sneha Ramakrishna, … impact number plateslist string new list stringWebbOne of the expert panel members was Sharon Benzeno, Ph.D., chief commercial officer of Immune Medicine at Adaptive Biotechnologies, who offered encouraging information. She felt that our approach was too centered on antibody responses and that it would be possible to identify biochemical markers of vaccine-induced cellular immunity in the … list string to string array javaWebb3 feb. 2024 · Sharon Benzeno, PhD is the Chief Business Development Officer and leads the Drug Discovery group of Adaptive Biotechnologies. Prior to joining Adaptive in 2014, Sharon was Senior Director at Elsevier Inc., a healthcare informatics company. Prior to Elsevier, Sharon co-led the oncology business unit at Capgemini SE, a consulting and … impact nursing academy